As we have previously reported, in response to the COVID-19 pandemic, the Minister of Health had made interim orders pursuant to the Food and Drugs Act to address the significant risk to health posed by shortages in 2020 and 2021. In anticipation of the expiry of Interim Order No. 2, Regulations Amending Certain Regulations Concerning Drugs and Medical Devices (Shortages) (the “Regulations”) were promulgated in 2021, with some provisions set to come into force later. Health Canada has issued a Notice regarding the Regulations, which includes an explanation of how the amendments differ from the previous now-expired interim orders.
On March 2, 2022, provisions of the Regulations regarding the following subjects, among others, came into force:
- exceptional importation and sale of drugs and medical devices
- amendment to the Certificate of Supplementary Protection Regulations (to carve-out from the definition of “authorization for sale” permission to sell a drug under the Regulations)
- mandatory reporting of shortages and discontinuations of specified medical devices and the power to compel information on medical device shortages
Health Canada has announced a new guidance for drugs: Guide to the exceptional importation and sale of drugs in response to drug shortages (GUI-0148). All products on the List of drugs for exceptional importation and sale, including existing products, will now have an end of importation date, but are allowed to be sold in Canada until the product expires.
Health Canada has also released related guidance documents for medical devices:
- Guide to reporting medical device shortages and discontinuations
- Guidance for exceptional importation and sale of medical devices
Additionally, on February 21, 2022, Health Canada made a further interim order re: medical devices: Interim Order No. 3 Respecting the Importation and Sale of Medical Devices for Use in Relation to COVID-19 (see our previous article about steps Health Canada has taken to facilitate availability of COVID-19 health products).
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance group.
Related Publications & Articles
-
Federal Court sets aside decision by the Minister of Health to issue RUZURGI NOC for the second time
On March 10, 2022, for the second time, the Federal Court set aside a decision by the Minister of Health (Minister) to issue Médunik Canada (Médunik) a Notice of Compliance (NOC) for its amifampridine...Read More -
Competition Bureau resolves misleading performance claims case
On April 27, 2022, the Competition Bureau announced that it has reached a settlement agreement with NuvoCare Health Sciences Inc and its founder (collectively “NuvoCare”), who were found to have made ...Read More -
Supreme Court of Canada denies leave to appeal refusal of NHP licence for BOLUOKE
On May 12, 2022, the Supreme Court of Canada dismissed an application by Canada RNA Biochemical (C-RNA) for leave to appeal (Docket No. 39994) a decision of the Federal Court of Appeal relating to the...Read More